Richard Stone

Featured in: Favicon

nature.com Favicon

smh.com.au Favicon

military.com Favicon

science.org Favicon

mdedge.com Favicon

modernhealthcare.com Favicon

ashpublications.org Favicon

ascopost.com + 7 more

Articles

Venous thromboembolism in adolescents and young adults with acute lymphoblastic leukemia treated on a pediatric-inspired regimen - Blood Cancer Journal

Oct 30, 2024 | nature.com | Shai Shimony |Hari Raman |Jonathan Paolino |Richard Stone |Jean M. Connors |Daniel DeAngelo

AbstractAsparaginase (ASP)-containing regimens for acute lymphoblastic leukemia (ALL) are associated with venous thromboembolism (VTE). We evaluated the prevalence, risk factors, role of prophylaxis and clinical impact of VTE among adolescents and young adult (AYA) patients (15–50 years) treated on Dana-Farber Cancer Institute (DFCI) ALL protocols.
Multiomic profiling identifies predictors of survival in African American patients with acute myeloid leukemia - Nature Genetics

Oct 4, 2024 | nature.com | Maarten WJ Fornerod |Deedra Nicolet |Benjamin Kelly |Krzysztof Mrózek |Jean F. Kloppers |Anne-Cecilia van Marle | +21 more

AbstractGenomic profiles and prognostic biomarkers in patients with acute myeloid leukemia (AML) from ancestry-diverse populations are underexplored. We analyzed the exomes and transcriptomes of 100 patients with AML with genomically confirmed African ancestry (Black; Alliance) and compared their somatic mutation frequencies with those of 323 self-reported white patients with AML, 55% of whom had genomically confirmed European ancestry (white; BeatAML).
Subunit-specific analysis of cohesin-mutant myeloid malignancies reveals distinct ontogeny and outcomes - Leukemia

Jul 20, 2024 | nature.com | Johann-Christoph Jann |Benjamin S. Braun |Shai Shimony |Richard Stone |Daniel DeAngelo |Jacqueline Garcia | +1 more

AbstractMutations in the cohesin complex components (STAG2, RAD21, SMC1A, SMC3, and PDS5B) are recurrent genetic drivers in myelodysplastic neoplasm (MDS) and acute myeloid leukemia (AML). Whether the different cohesin subunit mutations share clinical characteristics and prognostic significance is not known.
Molecular ontogeny underlies the benefit of adding venetoclax to hypomethylating agents in newly diagnosed AML patients - Leukemia

Mar 27, 2024 | nature.com | Shai Shimony |Jacqueline Garcia |Marlise R. Luskin |Donna S. Neuberg |Daniel DeAngelo |Richard Stone

AbstractThe clinical impact of molecular ontogeny in acute myeloid leukemia (AML) was defined in patients treated with intensive chemotherapy. In a cohort of 314 newly diagnosed AML patients, we evaluated whether molecular ontogeny subgroups have differential benefit of venetoclax (VEN) added to hypomethylating agents (HMA). In secondary ontogeny (n = 115), median overall survival (OS)(14.1 vs. 6.9 months, P = 0.0054), composite complete remission (cCR 61% vs.
Hypomethylating agents plus venetoclax compared with intensive induction chemotherapy regimens in molecularly defined secondary AML - Leukemia

Feb 20, 2024 | nature.com | Shai Shimony |Jan Philipp Bewersdorf |Rory M. Shallis |Guido Marcucci |Daniel DeAngelo |Donna S. Neuberg | +1 more

AbstractMolecularly defined secondary acute myeloid leukemia is associated with a prior myeloid neoplasm and confers a worse prognosis. We compared outcomes of molecularly defined secondary AML patients (n = 395) treated with daunorubicin and cytarabine (7 + 3, n = 167), liposomal daunorubicin and cytarabine (CPX-351, n = 66) or hypomethylating agents (HMA) + venetoclax (VEN) (n = 162). Median overall survival (OS) was comparable between treatment groups among patients aged >60 years.
Clinical evaluation of complete remission (CR) with partial hematologic recovery (CRh) in acute myeloid leukemia: a report of 7235 patients from seven cohorts | Leukemia

Jan 23, 2024 | nature.com | Jacob Appelbaum |Ing S. Tiong |Stephen B. Ting |Richard Stone |Guillermo Garcia-Manero |Guido Marcucci | +4 more

This is a preview of subscription content, access via your institution Access options Subscribe to this journal Receive 12 print issues and online access 251,40 € per year only 20,95 € per issue Rent or buy this article Prices vary by article type from$1.95 to$39.95 Prices may be subject to local taxes which are calculated during checkout Data availability For original, de-identified data and/or computer code (R) for analyses please contact the corresponding author ([email protected])....
MEN1 mutations mediate clinical resistance to menin inhibition - Nature

Mar 15, 2023 | nature.com | Daniela V. Wenge |Homa Rahnamoun |Richard Stone |Wenbin Xiao |Holly A. Gamlen |Aaron J. Stonestrom | +6 more

AbstractChromatin-binding proteins are critical regulators of cell state in haematopoiesis1,2. Acute leukaemias driven by rearrangement of the mixed lineage leukaemia 1 gene (KMT2Ar) or mutation of the nucleophosmin gene (NPM1) require the chromatin adapter protein menin, encoded by the MEN1 gene, to sustain aberrant leukaemogenic gene expression programs3,4,5.
Updating the American Society of Hematology guidelines for treating older adults with acute myeloid leukemia

Feb 7, 2023 | ashpublications.org | Richard Stone

TO THE EDITOR: The American Society of Hematology (ASH) 2020 guidelines for treating newly diagnosed acute myeloid leukemia (AML) in older adults answered 6 critical treatment questions concerning choices in induction treatment approach, postremission therapy, and palliative care. A guiding principle of the recommendations was to consider conversations that occur between a provider and a patient in making treatment decisions throughout the patient’s disease course.

Contact details

Emails

[email protected]

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →